在喘中可治疗的特征和治疗选择
Shivani Setur Kanabar1, Ian Douglas Pavord1, Timothy Stopford Christopher Hinks1
1Respiratory Medicine Unit, Experimental Medicine Division, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK; National Institute for Health and Care Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.
Respiratory medicine
|February 28, 2026
概括
个性化医疗改变了喘护理,认识到它是一种复杂的疾病,具有多种可治疗的特征. 识别和管理这些特征可以改善患有严重或难以治疗喘的患者的治疗结果.
科学领域:
- 肺部病理学 肺部病理学
- 内部医学 内部医学
- 遗传学 是一个遗传学.
背景情况:
- 喘管理正在向个性化医疗发展.
- 喘现在被理解为一种异质性疾病,具有复杂的潜在生物过程.
- 严重和难以治疗的喘越来越容易通过新的治疗方法来控制.
研究的目的:
- 审查喘中可治疗特征的概念.
- 讨论这些特征的病理学,诊断和管理.
- 为整体严重喘护理提供结构化的方法.
主要方法:
- 关于喘可治疗特征的当前证据的文献综述.
- 分析生物过程和与其他疾病的相互关系.
- 对当前证据缺口和未来研究方向的调查.
主要成果:
- 喘管理正在从一种适合所有人的方法转向个性化策略.
- 识别和管理特定的生物过程 (可治疗的特征) 是有效控制喘的关键.
- 了解并发症及其对喘的影响至关重要.
结论:
- 可治疗特征的方法为管理严重喘提供了一个结构化的框架.
- 个性化医疗,专注于个体生物过程,提高治疗效率.
- 需要进一步的研究来解决证据缺陷,并开发针对性治疗严重喘.
相关概念视频
Asthma-IV: Diagnostic and Management
3.2K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K
Asthma-I: Introduction
3.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.6K
Asthma-II: Pathophysiology and Classification
4.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.7K
Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.1K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K
Antiasthma Drugs: Leukotriene Modifiers
2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.0K


